BTIG raised the firm’s price target on Protagonist Therapeutics (PTGX) to $73 from $67 and keeps a Buy rating on the shares. Positive VERIFY data were announced on Monday, consistent with the firm’s expectations ahead of data, the analyst tells investors in a research note. The firm noted that all endpoints were met, including the key secondary endpoint of phlebotomy rate which was the pre-specified primary endpoint for European regulatory agencies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating
- Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential
- Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook
- Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships
- Protagonist Therapeutics: Buy Rating Backed by Promising Trials, Strategic Partnerships, and Strong Financial Position